May 7, 2002Circulation
Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis
Key result
In hyperlipidemic rabbits, eplerenone improved peak relaxations to acetylcholine (82% vs 61%; P<0.01) and normalized superoxide generation, indicating improved endothelial function.
Why the study?
Does eplerenone improve endothelial function and reduce oxidative stress in a rabbit model of diet-induced atherosclerosis?
Structured PICO
Does eplerenone improve endothelial function and reduce oxidative stress in a rabbit model of diet-induced atherosclerosis?
P
Population
New Zealand rabbits on normal chow or 1% cholesterol diets
I
Intervention
Eplerenone (50 mg/kg twice daily) for 6 weeks
C
Comparator
Placebo
O
Outcome
Superoxide (O2·−) generation, NADH and NADPH oxidase activity, and peak relaxations to acetylcholinesurrogate
Main Result
Absolute Event Rate: 82% vs 61%
p-value: p=<0.01
Mineralocorticoid receptor antagonism with eplerenone improves endothelial function and reduces oxidative stress in a rabbit model of early atherosclerosis.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Supports endothelial benefits of eplerenone in atherosclerosis models; leaves open translation to human disease.
Cite This Study
Rajagopalan et al. (2002) studied Experimental Atherosclerosis. Selective aldosterone receptor antagonist (eplerenone) vs. Placebo was evaluated on Peak relaxations to the endothelial-dependent agonist acetylcholine (p=<0.01). In hyperlipidemic rabbits, eplerenone improved peak relaxations to acetylcholine (82% vs 61%; P<0.01) and normalized superoxide generation, indicating improved endothelial function.